Review



이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제  (Gilead Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Gilead Sciences 이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제
    이에 따라 Bictegravir Emtricitabine Taf를 결합한 Biktarvy 나 Dolutegravir 기반의 복합제, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 470 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Biktarvy/pmc12749152-179-0-4
    Average 99 stars, based on 470 article reviews
    이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제 - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    other:

    Article Title: The effect of changing to Bictegravir on lipids using real world data: A brief report.
    Article Snippet: Prior work comparing the efficacy and safety of Biktarvy and dolutegravir in treatment-naïve individuals demonstrated that Biktarvy-treated patients had significant increases in TC and LDL after 96 weeks compared to dolutegravir/abacavir/lamuvidine.10 Stellbrink et al.11 also demonstrated no significant difference in lipid change between treatment naïve individuals in those randomized to Biktarvy or tenofovir alfenamide/emtricitabine/dolutegravir.

    Article Title: Extrapulmonary pneumocystosis in an antiretroviral therapy-naïve, HIV-positive patient.
    Article Snippet: On day 43, we adinistered dolutegravir 50 mg and Descovy HT (emtricitabine [200 g] and tenofovir alafenamide fumarate [25 mg]) and introduced PJP prophylactic regimen with TMP-SMX (1 single-strength tablet aily).

    Infection:

    Article Title: Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof
    Article Snippet: In some embodiments, the patient with the human immunodeficiency virus can be treated with atazanavir, ritonavir, or Truvada® in combination with a compound described herein. .. In some embodiments, the patient infected with human immunodeficiency virus can be treated with the combination of dolutegravir, Truvada® and a compound described herein. ..

    Virus:

    Article Title: Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof
    Article Snippet: In some embodiments, the patient with the human immunodeficiency virus can be treated with atazanavir, ritonavir, or Truvada® in combination with a compound described herein. .. In some embodiments, the patient infected with human immunodeficiency virus can be treated with the combination of dolutegravir, Truvada® and a compound described herein. ..



    Similar Products

    2 mercaptoethanol sigma aldrich m3148 dolutegravir dtg  (MedChemExpress)
    94
    MedChemExpress 2 mercaptoethanol sigma aldrich m3148 dolutegravir dtg
    2 Mercaptoethanol Sigma Aldrich M3148 Dolutegravir Dtg, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir/pm42224077-90-126-132
    Average 94 stars, based on 1 article reviews
    2 mercaptoethanol sigma aldrich m3148 dolutegravir dtg - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    hy 13238 lamivudine 3tc bei resources hrp 8146 abacavir abc  (MedChemExpress)
    94
    MedChemExpress hy 13238 lamivudine 3tc bei resources hrp 8146 abacavir abc
    Hy 13238 Lamivudine 3tc Bei Resources Hrp 8146 Abacavir Abc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir/pm42224077-90-133-132
    Average 94 stars, based on 1 article reviews
    hy 13238 lamivudine 3tc bei resources hrp 8146 abacavir abc - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    dolutegravir dtg  (MedChemExpress)
    94
    MedChemExpress dolutegravir dtg
    Dolutegravir Dtg, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir/bio_rxiv__64898__2026__04__21__719790-120-23-25
    Average 94 stars, based on 1 article reviews
    dolutegravir dtg - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    antiretroviral drugs dtg  (Toronto Research Chemicals)
    94
    Toronto Research Chemicals antiretroviral drugs dtg
    Antiretroviral Drugs Dtg, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir/pm41904696-60-8-11
    Average 94 stars, based on 1 article reviews
    antiretroviral drugs dtg - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    abc  (MedChemExpress)
    94
    MedChemExpress abc
    Multistage exposure to increasing doses <t>of</t> <t>DTG+ABC</t> + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Abc, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir/pmc13034632-56-18-19
    Average 94 stars, based on 1 article reviews
    abc - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    film coated dolutegravir  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health film coated dolutegravir
    Multistage exposure to increasing doses <t>of</t> <t>DTG+ABC</t> + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Film Coated Dolutegravir, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/dolutegravir/10__1097_slash_qai__0000000000003862-40-27-2
    Average 86 stars, based on 1 article reviews
    film coated dolutegravir - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dolutegravir  (Wolters Kluwer Health)
    86
    Wolters Kluwer Health dolutegravir
    Multistage exposure to increasing doses <t>of</t> <t>DTG+ABC</t> + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Dolutegravir, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/dolutegravir/10__1097_slash_qai__0000000000003862-60-20-2
    Average 86 stars, based on 1 article reviews
    dolutegravir - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    dolutegravir  (MedChemExpress)
    94
    MedChemExpress dolutegravir
    Multistage exposure to increasing doses <t>of</t> <t>DTG+ABC</t> + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Dolutegravir, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Dolutegravir+sodium/pm41636646-38-0-5
    Average 94 stars, based on 1 article reviews
    dolutegravir - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제  (Gilead Sciences)
    99
    Gilead Sciences 이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제
    Multistage exposure to increasing doses <t>of</t> <t>DTG+ABC</t> + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    이에 따라 Bictegravir Emtricitabine Taf를 결합한 Biktarvy 나 Dolutegravir 기반의 복합제, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dolutegravir/Biktarvy/pmc12749152-179-0-4
    Average 99 stars, based on 1 article reviews
    이에 따라 bictegravir emtricitabine taf를 결합한 biktarvy 나 dolutegravir 기반의 복합제 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Multistage exposure to increasing doses of DTG+ABC + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: ASN NEURO

    Article Title: Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages

    doi: 10.1080/17590914.2026.2647877

    Figure Lengend Snippet: Multistage exposure to increasing doses of DTG+ABC + 3TC inhibits OL maturation. (a) Diagram of multistage treatment paradigm with DTG+ABC + 3TC during OPC proliferation and OL differentiation. (b) Representative images of differentiated OLs after multistage treatment with DTG+ABC + 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + (c) and PLP + (d) cells shows significantly fewer differentiated OLs after multistage exposure to DTG+ABC + 3TC without an effect on total number of DAPI + cells (e), n = 3/group. f) Representative immunoblots of MBP and PLP after multistage exposure to DTG+ABC + 3TC. Densitometry analyses show significantly less MBP (g) and PLP (h) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: In this study, OPCs were treated with the antiretroviral drugs DTG (Toronto Research Chemicals, D528800 and MedChemExpress, HY-13238), ABC (MedChemExpress, HY-17423), 3TC (MedChemExpress, HY-B0250), or a combination of all 3 drugs (identified as cART).

    Techniques: Western Blot, Expressing

    DTG, but not ABC or 3TC, significantly impairs OL maturation after multistage exposure. (a) Representative images of differentiated OLs after multistage treatment with DTG, ABC, or 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + and PLP + cells shows significantly fewer differentiated OLs without a change in DAPI after multistage exposure to DTG (b-d) but not ABC (e-g) or 3TC (h-j), n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. ** p < 0.01, **** p < 0.0001.

    Journal: ASN NEURO

    Article Title: Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages

    doi: 10.1080/17590914.2026.2647877

    Figure Lengend Snippet: DTG, but not ABC or 3TC, significantly impairs OL maturation after multistage exposure. (a) Representative images of differentiated OLs after multistage treatment with DTG, ABC, or 3TC and immunostained for GalC (green), PLP (red), and DAPI (blue). Scale bar = 75 µm. Quantification of the number of GalC + and PLP + cells shows significantly fewer differentiated OLs without a change in DAPI after multistage exposure to DTG (b-d) but not ABC (e-g) or 3TC (h-j), n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. ** p < 0.01, **** p < 0.0001.

    Article Snippet: In this study, OPCs were treated with the antiretroviral drugs DTG (Toronto Research Chemicals, D528800 and MedChemExpress, HY-13238), ABC (MedChemExpress, HY-17423), 3TC (MedChemExpress, HY-B0250), or a combination of all 3 drugs (identified as cART).

    Techniques:

    DTG, but not ABC or 3TC, significantly reduces myelin protein expression after multistage exposure. (a) Representative immunoblots of MBP and PLP after multistage exposure to DTG (800 nM, 8 µM, or 24 µM). Densitometry analyses show significantly less MBP after exposure to 800 nM, 8 µM, or 24 µM DTG (b) and PLP after exposure to 24 µM DTG (c), n = 3/group. (d) Representative immunoblots of MBP and PLP after multistage exposure to ABC (150 nM, 1.5 µM, or 4.5 µM). Densitometry analyses show no changes in MBP (e) or PLP (f) expression, n = 3/group. g) Representative immunoblots of MBP and PLP after multistage exposure to 3TC (600 nM, 6 µM, or 18 µM). Densitometry analyses show no changes in MBP (h) or PLP (i) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. ** p < 0.01, **** p < 0.0001.

    Journal: ASN NEURO

    Article Title: Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages

    doi: 10.1080/17590914.2026.2647877

    Figure Lengend Snippet: DTG, but not ABC or 3TC, significantly reduces myelin protein expression after multistage exposure. (a) Representative immunoblots of MBP and PLP after multistage exposure to DTG (800 nM, 8 µM, or 24 µM). Densitometry analyses show significantly less MBP after exposure to 800 nM, 8 µM, or 24 µM DTG (b) and PLP after exposure to 24 µM DTG (c), n = 3/group. (d) Representative immunoblots of MBP and PLP after multistage exposure to ABC (150 nM, 1.5 µM, or 4.5 µM). Densitometry analyses show no changes in MBP (e) or PLP (f) expression, n = 3/group. g) Representative immunoblots of MBP and PLP after multistage exposure to 3TC (600 nM, 6 µM, or 18 µM). Densitometry analyses show no changes in MBP (h) or PLP (i) expression, n = 3/group. One-way ANOVA with Dunnett post-hoc test to compare all treatment groups to DMSO. ** p < 0.01, **** p < 0.0001.

    Article Snippet: In this study, OPCs were treated with the antiretroviral drugs DTG (Toronto Research Chemicals, D528800 and MedChemExpress, HY-13238), ABC (MedChemExpress, HY-17423), 3TC (MedChemExpress, HY-B0250), or a combination of all 3 drugs (identified as cART).

    Techniques: Expressing, Western Blot